At the annual meeting of the American Association of Cancer Researchers, presenters discuss strategies to improve the safety and effectiveness of reengineered T cells in eradicating tumors.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Krishan Maggon 's curator insight,
February 19, 2015 3:58 AM
Surgery (Oxford)
Available online 14 February 2015 In Press, Corrected Proof — Note to users Cancer treatment Principles of cancer treatment by immunotherapyJenny Fernando, Satish Kumar doi:10.1016/j.mpsur.2015.01.004Get rights and content
Krishan Maggon 's curator insight,
January 30, 2015 8:49 AM
Molecular Immunology
Available online 13 January 2015 In Press, Corrected Proof — Note to users Review Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic ☆Connie P.M. Duonga, b, c, Carmen S.M. Yonga, b, Michael H. Kershawa, b, c, d, Clare Y. Slaneya, b, 1, , ,Phillip K. Darcya, b, c, d, 1, , doi:10.1016/j.molimm.2014.12.009
Krishan Maggon 's curator insight,
July 19, 2014 5:11 PM
The top 5 cancer types listed by the number of immunotherapy clinical trials, derived from ClinTrials.gov
Neoplasm Glandular/Epithelial 228 Neoplasm Nerves 203 Carcinoma 192 Melanoma 127 Leukemia 108
Gilbert C FAURE's comment,
July 20, 2014 3:42 AM
nice synthesis! I had recently a similar idea to write "capsules" on topics of interest
Krishan Maggon 's comment,
July 21, 2014 10:17 AM
Very good idea, i wish there was a way to collaborate and place for collaborative efforts. thanks and best regards
|
Krishan Maggon 's curator insight,
March 18, 2015 5:44 AM
Trends in Immunology Volume 36, Issue 2, February 2015, Pages 71–80 Review Targeting T cell metabolism for therapyDavid O'Sullivan, Erika L. Pearce doi:10.1016/j.it.2014.12.004
Krishan Maggon 's curator insight,
February 18, 2015 2:25 AM
Pharmaceuticals 2015, 8(1), 40-61; doi:10.3390/ph8010040 Reviewγδ T Cell Immunotherapy—A ReviewHirohito Kobayashi 1,* and Yoshimasa Tanaka 2,*1Transfusion Medicine and Cell Processing, Department of Urology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan2Center for Therapeutic Innovation, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan*Authors to whom correspondence should be addressed; E-Mails: hirohitokobayashi-jua@umin.ac.jp (H.K.); ystanaka@nagasaki-u.ac.jp (Y.T.); Tel.: +81-3-3353-8111 (ext. 25035) (H.K.); +81-95-819-2890 (Y.T.); Fax: +81-3-5269-7685 (H.K.); +81-95-819-2420 (Y.T.).Academic Editor: Shin MineishiReceived: 6 January 2015 / Accepted: 2 February 2015 / Published: 12 February 2015- See more at: http://www.mdpi.com/1424-8247/8/1/40/htm#sthash.jOThc0Xd.dpuf
Krishan Maggon 's curator insight,
November 6, 2014 2:43 AM
Immunology and Cell Biology advance online publication 4 November 2014; doi: 10.1038/icb.2014.93 Bispecific T-cell engagers for cancer immunotherapyAmelia M Huehls1, Tiffany A Coupet1 and Charles L Sentman1 1Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA Correspondence: Professor CL Sentman, Department of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, One Medical Center Drive, Lebanon, NH 03756, USA. E-mail:charles.sentman@dartmouth.edu Received 17 August 2014; Revised 29 September 2014; Accepted 29 September 2014
Krishan Maggon 's comment,
July 16, 2014 11:24 AM
thanks a lot, I think this is an important development and a big vote of confidence from big pharma in Cellectis CAR and bioengineered T cells. Great day for French R&D and start up companies in Immunotherapy.
Krishan Maggon 's comment,
July 16, 2014 11:26 AM
I wonder why the total number of visitors and page view remains too low. I think it is the absence from the USA market of Scoop it?
Gilbert C FAURE's comment,
July 16, 2014 12:05 PM
what are you refereeing to? I will send you the draft of a summary for a meeting Science&You next year where I want to submit a talk or a session about curation. Check your e-mail to-morrow.
|
CAR T Cell immunotherapy, TIL, ATC, TCR unpredictable toxicity at AACR 2015